IL6 and COVID-19: Evidence of how high levels of interleukin-6 (IL-6) stimulate megakaryocytopoiesis in the bone marrow and abnormal lung immunothrombosis in severe COVID-19 patients has been proven in postmortem and biopsy examinations [20].